ClinicalTrials.gg
Active, not recruitingNCT03227042Updated Oct 26, 2022

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

An observational study in Mucopolysaccharidosis Type IIIB, sponsored by Allievex Corporation. Active, not recruiting at 9 sites in 9 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by Allievex Corporation · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
44
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.

Enrollment
5th of 19
44 · median 30
Started
2017
with 1 other
Observational
19 of 43
5 open now
Primary completion
2025-10
later than 1 of 14 live
Registered
20th of 43
by date
Lead sponsor
5 of 43
Allievex Corporation

Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 5th largest by enrollment of the 19 observational ones that give a count, is one of 2 that started in 2017, is one of 19 observational ones, reaches primary completion later than 1 of the 14 other live ones, and was the 20th registered.

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

Browse Mucopolysaccharidosis III studies →

Open to participants now

12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Mucopolysaccharidosis III with a site in United States, or all of them as a file.
02

Study summary

This is a natural history study for children up to 18 years of age who have been diagnosed with Mucopolysaccharidosis Type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B). Mucopolysaccharidosis type IIIB is a severe neurodegenerative disorder. The information gathered from this trial may help inform the design and interpretation of subsequent interventional studies. No clinical intervention or study drug is provided by Allievex in this study.

03

Conditions studied

  • Mucopolysaccharidosis Type IIIB

Keywords

  • Sanfilippo Syndrome Type B
  • MPS IIIB
  • MPS 3 B
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males and Females with a documented diagnosis of MPSIIIB

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have deficient NAGLU enzyme activity at Baseline. Blood for NAGLU enzyme activity will be collected and analyzed centrally.
  • Is up to 18 years of age
  • Written from parent or legal guardian and assent from subject, if required
  • Has the ability to comply with protocol requirements, in the opinion of the investigator

Exclusion criteria

Exclusion Criteria:

  • Has another neurological illness that may have caused cognitive decline (e.g., trauma, meningitis, or hemorrhage) before study entry
  • Has received stem cell, gene therapy, or enzyme replacement therapy for MPS IIIB
  • Has received any medication within 30 days prior to the Baseline visit or is scheduled to receive any investigational drug during the course of the study
  • Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with protocol requirements, the subject's wellbeing or safety, or the interpretability of the subject's clinical data.
  • Is currently participating in another natural history study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
44 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Neurocognitive function

    A neurodevelopmental assessment will be performed using standardized developmental tests to provide quantifiable measures of neurocognitive function.

    Time frame: Baseline + every 24 weeks for up to 240 weeks

  2. Behavioral function

    Disease-related behaviors will be assessed using an MPS IIIB specific behavior rating scale.

    Time frame: Baseline + every 24 weeks for up to 240 weeks

  3. Quality of Life Tests

    Multiple QoL tools will be used to capture physical, mental, and social well-being of the patient as well as to examine the impact of the patient's disease on the parent/guardian and family.

    Time frame: Baseline + every 24 weeks for up to 240 weeks

  4. Sleep habits

    Patient sleep habits will be assessed using Children's Sleep Habits Questionnaires (CSHQ).

    Time frame: Baseline + every 24 weeks for up to 240 weeks

  5. Disease-specific Biomarkers

    Urine sample for glycosaminoglycans (GAGs) and creatinine.

    Time frame: Baseline + every 24 weeks for up to 240 weeks

  6. Biochemical, Molecular, Cellular and Genetic Markers of Disease Burden

    Blood and urine samples will be used to evaluate biochemical, molecular cellular, and genetic/genomic aspects of MPS IIIB.

    Time frame: Once (at baseline visit)

07

Study locations

9 sites
08

References and documents

Publications

  • Okur I, Ezgu F, Giugliani R, Muschol N, Koehn A, Amartino H, Harmatz P, de Castro Lopez MJ, Couce ML, Lin SP, Batzios S, Cleary M, Solano M, Peters H, Lee J, Nestrasil I, Shaywitz AJ, Maricich SM, Kuca B, Kovalchin J, Zanelli E. Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB. J Pediatr. 2022 Oct;249:50-58.e2. doi: 10.1016/j.jpeds.2022.06.005. Epub 2022 Jun 13. PubMed 35709957 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2017 (actual). Primary completion is estimated for Oct 2025, 95 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2017
First posted
Jul 24, 2017
StartActual
Nov 16, 2017
Primary completionEst.
Oct 2025
CompletionEst.
Dec 2025
Last update
Oct 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03227042
Lead sponsor
Allievex Corporation
Responsible party
Sponsor
First posted
Jul 24, 2017
Start date
Nov 16, 2017
Primary completion
Oct 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 26, 2022

Study contacts

Medical Director, MD
study director · Allievex Medical Monitor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion